KeyBanc Reiterates a Buy Rating on Inovalon

By George MacDonald

In a report issued on May 20, Donald Hooker from KeyBanc reiterated a Buy rating on Inovalon (NASDAQ: INOV), with a price target of $26. The company’s shares closed last Friday at $18.27.

According to TipRanks.com, Hooker is a 4-star analyst with an average return of 6.9% and a 53.3% success rate. Hooker covers the Technology sector, focusing on stocks such as Greenway Medical Technologies, Medidata Solutions, and Quality Systems.

Inovalon has an analyst consensus of Hold, with a price target consensus of $26

.

The company has a one year high of $29 and a one year low of $15.12. Currently, Inovalon has an average volume of 628.1k.

Like KeyBanc`s latest rating, based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INOV in relation to earlier this year. Earlier this month, Keith Dunleavy, a the CEO & Chairman of the Board of INOV bought 30,000 shares for a total of $500,440.

Inovalon Holdings, Inc. operates as a technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and improvement in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape. Its powerful platform drives high-value impact, improving quality and economics for health plans, hospitals, physicians, patients, pharmaceutical companies, and researchers. Inovalon Holdings was founded on September 11, 2014 and is headquartered in Bowie, MD.